4Q: Modest profitability beat; upbeat outlook

研报英文原文证据摘录

4Q: Modest profitability beat; upbeat outlook

Flashnote Torrent Pharmaceuticals

independence of Macquarie Research’s product. However, recipients of Macquarie Research should be aware of this potential conflict of interest. New Zealand: In New

Zealand, research is issued and distributed by Macquarie Securities (NZ) Ltd, a NZX Firm. United Kingdom and the EEA: In the United Kingdom and the European

Economic Area, research is distributed by Macquarie Capital (Europe) Ltd, which is authorised and regulated by the Financial Conduct Authority (No. 193905). Hong

Kong & Mainland China: In Hong Kong, research is issued and distributed by Macquarie Capital Limited, which is licensed and regulated by the Securities and Futures

Commission. Only non-A share research is distributed into Mainland China by Macquarie Capital Limited. Japan: In Japan, research is issued and distributed by Macquarie

Capital Securities (Japan) Limited (Tokyo Branch), the Financial Instruments Business Operator, registered with the Financial Services Agency (Registration number:

Kanto Financial Bureau (FIBO) No. 231), the member of the Tokyo Stock Exchange, Inc. , Osaka Exchange, Inc. and the member of Japan Securities Dealers Association. Its

Designated Dispute Resolution Institution is Financial Instruments Mediation Assistance Center ("FINMAC"). Indonesia: In Indonesia, research is issued and distributed by

PT Macquarie Sekuritas Indonesia, a licensed securities company and regulated by Financial Services Authority (Otoritas Jasa Keuangan) and is a member of the Indonesia

Stock Exchange. The securities discussed in this report may not be suitable for all investors. Malaysia: In Malaysia, research is issued and distributed by Macquarie

Capital Securities (Malaysia) Sdn. Bhd.